BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial

Reuters

May 07, 2025

BUZZ-<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> soars after cancer drug meets main goal in mid-stage trial

** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket

** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial

** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX

** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body

** Co says the drug has been tested in over 140 patients and was well-tolerated

** As of last close, stock down 22.3% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533546989"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533546989\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533546989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533546989","market":"us","top_or_hot":-1,"title":"BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> soars after cancer drug meets main goal in mid-stage trial</title></head><body><p>** Shares of cancer therapy developer Theriva Biologics <span>TOVX.A</span> rise 80% to $2.45 premarket</p><p>** Co <span>says</span> its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial</p><p>** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX</p><p>** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body</p><p>** Co says the drug has been tested in over 140 patients and was well-tolerated</p><p>** As of last close, stock down 22.3% YTD</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-07 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/TOVX\">Theriva Biologics</a> soars after cancer drug meets main goal in mid-stage trial</title></head><body><p>** Shares of cancer therapy developer Theriva Biologics <span>TOVX.A</span> rise 80% to $2.45 premarket</p><p>** Co <span>says</span> its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial</p><p>** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX</p><p>** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body</p><p>** Co says the drug has been tested in over 140 patients and was well-tolerated</p><p>** As of last close, stock down 22.3% YTD</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TOVX","symbol_name":"Theriva Biologics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL4N3RF15B:1","article_id":"2533546989","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533546989","pubTimestamp":1746617377,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body** Co says the drug has been tested in over 140 patients and was well-tolerated** As of last close, stock down 22.3% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TOVX":"Theriva Biologics","BK4139":"生物科技"},"translate_title":"癌症药物达到中期试验主要目标后，Theriva Biologics股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TOVX":0.9},"content_text":"BUZZ-Theriva Biologics soars after cancer drug meets main goal in mid-stage trial** Shares of cancer therapy developer Theriva Biologics TOVX.A rise 80% to $2.45 premarket** Co says its experimental cancer drug, zabilugene almadenorepvec, when used with chemotherapy, met the main goal of improved overall survival and reduced risk of disease progression, in a mid-stage trial** Patients who received the drug with standard chemotherapy lived longer, 10.8 months, compared to those who received only chemotherapy, 8.6 months - TOVX** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body** Co says the drug has been tested in over 140 patients and was well-tolerated** As of last close, stock down 22.3% YTD(Reporting by Kamal Choudhury in Bengaluru)((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}